
CNST
Healthcare · Biotechnology · $1.63B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2021
EPS trend, 90 days to now · -4.8% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 10, 2021 | Before the open | -0.80 | -0.84 | -5.2% |
| Feb 24, 2021 | After the close | -0.76 | -0.79 | -4.6% |
| Oct 29, 2020 | Before the open | -0.65 | -0.71 | -9.2% |
| Aug 5, 2020 | Before the open | -0.63 | -0.70 | -10.2% |
| May 6, 2020 | After the close | -0.65 | -0.61 | +6.3% |
| Mar 10, 2020 | After the close | -0.72 | -0.69 | +3.9% |
| Nov 6, 2019 | After the close | -0.82 | -0.82 | -0.3% |
| Aug 7, 2019 | After the close | -0.80 | -0.80 | +0.0% |
| May 8, 2019 | After the close | -0.80 | -0.75 | +6.3% |
| Mar 14, 2019 | After the close | -0.74 | -0.77 | -4.4% |
| Nov 8, 2018 | After the close | -0.68 | -0.81 | -18.8% |
| Aug 14, 2018 | After the close | -0.56 | -0.55 | +1.8% |
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It…